Release Date: 2024-03-25

Tuberculosis: Treatment

Ozlem Abakay (Author), Menduh Oruc (Author)

Release Date: 2024-03-25

Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis. Mycobacterium tuberculosis is transmitted by inhalation of droplets. Medication is the main component of TB treatment. When starting tuberculosis treatment, first a case definition is made and the treatment regimen is determined. The treatment regimen consists of two periods: an initial period and a maintenance period. [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inThoracic Infections
    First Page31
    Last Page37
    DOIhttps://doi.org/10.69860/nobel.9786053358930.4
    Page Count7
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing
    Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis. Mycobacterium tuberculosis is transmitted by inhalation of droplets. Medication is the main component of TB treatment.
    When starting tuberculosis treatment, first a case definition is made and the treatment regimen is determined. The treatment regimen consists of two periods: an initial period and a maintenance period. First-generation medications used in TB treatment: Isoniazid (INH), Rifampicin (RIF), pyrazinamide (PZA), ethambutol (EMB) and streptomycin. Secondary medications used in the treatment of resistant TB. Treatment success rate increases with directly observed treatment.

    Ozlem Abakay (Author)
    Associate Professor, Diyar Life Hospital
    https://orcid.org/0000-0003-0021-9670
    3Assoc. Prof. Dr. Ozlem Abakay is a scientist with a professional career spanning over twenty years and original contributions in the field of medical application of pulmonology. His work has led to the publication of more than 85 research articles, oral and poster presentations, and reviews. He is currently working at Private Diyarlife Dagkapi Hospital, in the Department of Chest Diseases. His special interests are thoracic infections and tuberculosis.

    Menduh Oruc (Author)
    Associate Professor, Dicle University
    https://orcid.org/0000-0001-5778-385X
    3Menduh ORUÇ completed his undergraduate education at Dicle University Faculty of Medicine between 1996-2001 and his thoracic surgery specialization at Dicle University Faculty of Medicine between 2004-2009. He started his academic career as an assistant professor at Dicle University Faculty of Medicine in 2013. He received the title of associate professor in 2019 and still continues as an academic staff member at the same university. Dr.Menduh ORUÇ is a member of the Turkish Thoracic Surgery Association, Turkish Thoracic Association, Turkish Respiratory Research Association, Turkish Lung Cancers Association, Turkish Pulmonary Hydatidology Association and EACTS. Skills:He plays chess well, speaks Turkish at a very good level, as well as English at an intermediate level.Apart from these, he focuses on agriculture and plants as a hobby.

    • Taylan M, Tanrikulu AC, Sezgi C, et al. The importance of chemoprophylaxis in tuberculosis: On occasion of eight cases in the same family. Dicle Med J 2013;40 (4): 651-654.

    • Fox W, Mitchison DA. Short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1975; 111:325-53.

    • Reference Book for the Control of Tuberculosis in Turkey, Republic of Turkey Ministry of Health, Ankara, 2003. https://verem. org.tr/uploads/pdf/tum-kitap. pdf (Date of access: 24.04.2024).

    • Tuberculosis Diagnosis and Treatment Guide, Republic of Turkey Ministry of Health Publication No: 1129, Ankara, May 2019. https://hsgm.saglik.gov.tr/depo/birimler/tuberkuloz db/ Dokumanlar/Rehberler/Tuberkuloz_Tani_ve_Tedavi_Rehberi.pdf (Date of access: 24.04.2024).

    • Nahid P, Dorman S E, Alipanah N, Barry P M, Brozek JL, Cattamanchi A, et al. Executive summary: official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016:63;853-867.

    • Prideaux B, Via LE, Zimmerman MD, et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med. 2015; 21:1223-7.

    • Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. Int J Tuberc Lung Dis. 2015; 19:1276-89.

    • Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-25.

    • Furin J, Gegia M, Mitnick C, et al. Eliminating the category II retreatment regimen from national tuberculosis programme guidelines: the Georgian experience. Bull World Health Organ 2012; 90:63–6.

    • Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampin and isoniazid twice a week for treatment of drug susceptible pulmonary tuberculosis: a randomized clinical trial. Lancet 2002; 360:528–34.

    • Mitchison DA. Assessment of New Sterilizing Drugs for Treating Pulmonary Tuberculosis by Culture at 2 Months. Am Rev Respir Dis 2003; 147:1062–3.

    • WHO. Handbook for the use of digital technologies to support. Tuberculosis medication adherence, WHO, Geneva, 2017.

    • Kelekçi, S, Karabel, M, Karabel, D, Hamidi C, Hoşoğlu S, Gürkan M F, et al. Bacillus Calmette– Guérin is a preventive factor in mortality of childhood tuberculous meningitis. International Journal of Infectious Diseases, 2014; 21, 1-4.

    • Aldridge BB, Barros-Aguirre D, Barry C E, Bates R H, Berthel S J, Boshoff H I, et al. The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 2021: Aug; 27(8):1333-7.

    • Dartois VA. Rubin EJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol 2022:20; 685–701

    Share This Chapter!